Phase I Study of the BRAF Inhibitor Vemurafenib in Combination With the Mammalian Target of Rapamycin Inhibitor Everolimus in Patients With BRAF-Mutated Malignancies.
- DOI
- 10.1200/po.18.00189
- Published
- 2018
- Container
- JCO precision oncology
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1200/po.18.00189,
title = {Phase I Study of the BRAF Inhibitor Vemurafenib in Combination With the Mammalian Target of Rapamycin Inhibitor Everolimus in Patients With BRAF-Mutated Malignancies.},
author = {Subbiah V and Sen S and Hess KR and Janku F and Hong DS and Khatua S and Karp DD and Munoz J and Falchook GS and Groisberg R and Tsimberidou AM and Sherman SI and Hwu P and Meric-Bernstam F},
year = {2018},
journal = {JCO precision oncology},
doi = {10.1200/po.18.00189},
url = {https://doi.org/10.1200/po.18.00189}
}RIS
TY - JOUR TI - Phase I Study of the BRAF Inhibitor Vemurafenib in Combination With the Mammalian Target of Rapamycin Inhibitor Everolimus in Patients With BRAF-Mutated Malignancies. AU - Subbiah V AU - Sen S AU - Hess KR AU - Janku F AU - Hong DS AU - Khatua S AU - Karp DD AU - Munoz J AU - Falchook GS AU - Groisberg R AU - Tsimberidou AM AU - Sherman SI AU - Hwu P AU - Meric-Bernstam F PY - 2018 JO - JCO precision oncology DO - 10.1200/po.18.00189 UR - https://doi.org/10.1200/po.18.00189 ER -
APA
V, S., S, S., KR, H., F, J., DS, H., S, K., DD, K., J, M., GS, F., R, G., AM, T., SI, S., P, H., & F, M. (2018). Phase I Study of the BRAF Inhibitor Vemurafenib in Combination With the Mammalian Target of Rapamycin Inhibitor Everolimus in Patients With BRAF-Mutated Malignancies.. JCO precision oncology. https://doi.org/10.1200/po.18.00189
Source records
- pubmed · retrieved 2026-09-26T17:07:06.131Z
- europe-pmc · retrieved 2026-09-26T17:07:06.143Z